In-depth research articles on peptide science, mechanisms of action, clinical studies, and practical research protocols.
Educational overview of retatrutide’s triple-pathway mechanism, why it is studied for metabolic disease, evidence context, and common safety discussion points.
In-depth educational guide to tirzepatide: dual GLP-1 and GIP agonism, clinical evidence context, tolerability, and how it differs from semaglutide.
Updated guide to BPC-157 covering mechanism, evidence limits, the FDA compounding ban (2024), and the first IV human safety study published in 2025. What changed and what it means for researchers.
Explains TB-500 in the context of thymosin beta-4 research, cell migration and tissue repair hypotheses, and why evidence claims need careful grading.
Educational introduction to pinealon: proposed neuroprotective and cognitive research angles, what is known from preclinical work, and limits of translation.
Explains epitalon/epithalon in longevity research conversations: common hypotheses, typical study types, and why aging-peptide topics need conservative interpretation.
SS-31 (elamipretide, brand name Forzinity) became the first FDA-approved mitochondria-targeting peptide in September 2025, cleared for Barth syndrome. This guide covers the cardiolipin mechanism, the TAZPOWER trial, and what approval means for broader longevity research interest.
Overview of thymosin alpha-1: immune modulation research, historical clinical interest, regulatory realities, and how to read TA1 discussions critically.
Explains GHK-Cu (copper tripeptide-1): extracellular matrix and collagen framing, cosmetic vs clinical contexts, and how to evaluate copper-peptide claims.
Explains recombinant human growth hormone versus GHRPs and GHRH analogs, why online discussions conflate them, and how to compare mechanisms responsibly.
Evidence-aware guide to PT-141 (bremelanotide): melanocortin receptor biology, how it differs from PDE5 drugs, and why medical supervision matters.
Orforglipron (brand name Foundayo) was FDA-approved April 1, 2026 — the first oral, non-peptide GLP-1 receptor agonist for weight loss. This guide explains what it is, how it differs from oral semaglutide, and what ATTAIN trial data showed.
Amycretin is a single-molecule GLP-1 and amylin receptor co-agonist from Novo Nordisk showing up to 24% body weight reduction in Phase 2. This guide explains the dual-mechanism rationale, Phase 2 data, and how it differs from CagriSema and tirzepatide.
Mazdutide is a GLP-1 and glucagon receptor dual agonist approved in China in 2025 for weight management and type 2 diabetes. This guide covers its mechanism, head-to-head semaglutide data, and what China approval means for global research interest.
In late 2024 the FDA banned 17+ peptides from US compounding pharmacies. Then on April 15, 2026, it removed 12 of them from the ban list for deeper PCAC expert review. This guide explains both developments and what they mean for researchers.
GLP-2 is the less-discussed incretin sibling of GLP-1, with a distinct mechanism focused on intestinal repair rather than weight loss. This guide covers apraglutide and glepaglutide, the two next-gen GLP-2 analogs with strong Phase 3 data for short bowel syndrome.
Evidence-aware category overview mapping peptides (Epithalon, GHK-Cu, Thymosin Alpha-1, MOTS-c, Humanin, SS-31) onto the Hallmarks of Aging framework — what each targets, and where the evidence actually sits.
Category overview of peptides researched in sexual and reproductive health contexts: PT-141 (bremelanotide), Melanotan II, and kisspeptin-10 — central vs vascular mechanisms and why they are not interchangeable.
Evidence-aware overview of Cerebrolysin: porcine-brain-derived peptide fraction studied in stroke, traumatic brain injury, and cognitive impairment contexts — mechanism, evidence maturity, and why it differs from single-sequence peptides.
Evidence-aware overview of Humanin: mitochondrial-derived peptide with cytoprotective, neuroprotective, and metabolic signaling roles — mechanism, research evidence, and relationship to MOTS-c.
Evidence-aware overview of kisspeptin-10: upstream hypothalamic regulator of GnRH, reproductive biology relevance, fertility research contexts, and why it is mechanistically distinct from melanocortin peptides.
Evidence-aware overview of Melanotan II: broad melanocortin receptor agonism, differences from PT-141, safety caveats, and why regulatory framing matters for this compound.
Evidence-aware overview of FOXO4-DRI: D-retro-inverso senolytic peptide designed to disrupt the FOXO4–p53 interaction, the 2017 Baar et al. study, mouse-level efficacy, and realistic clinical status.
Evidence-aware guide to cagrilintide and the CagriSema (cagrilintide + semaglutide) combination: amylin receptor biology, REDEFINE trial context, and how it differs from standalone GLP-1 therapy.
Evidence-aware overview of survodutide: dual GLP-1 and glucagon receptor agonism, Phase 2 obesity and MASH data, and how it compares to tirzepatide and retatrutide.
Map of the triple-agonist class (retatrutide and peers): why three receptors beat two, what the TRIUMPH data suggested, and how to compare with tirzepatide, CagriSema, and survodutide.
Side-by-side comparison of oral and injectable GLP-1 options in 2026: oral semaglutide, oral wegovy, orforglipron, and weekly injectable peptides. What actually differs beyond the needle.
Mechanistic and evidence-based comparison of semaglutide (selective GLP-1) and retatrutide (GLP-1/GIP/glucagon triple agonist): receptor biology, clinical data maturity, and where each compound fits.
Compare tirzepatide (GLP-1/GIP dual agonist) and retatrutide (GLP-1/GIP/glucagon triple agonist): receptor biology, efficacy data, and how the glucagon axis changes the comparison.
Compare ipamorelin (ghrelin receptor agonist) and sermorelin (GHRH analog): receptor targets, pulse behavior, and how to select the right GH-axis comparator.
Compare ipamorelin and CJC-1295 without DAC: receptor targets, pulse dynamics, stack logic, and protocol isolation strategy for GH-axis research.
Compare Selank and Semax: anxiolytic vs stimulatory cognitive profiles, GABA/serotonin vs dopamine/BDNF mechanisms, and how to choose a comparator.
Technical guide to interpreting a peptide Certificate of Analysis: HPLC purity, mass spectrometry identity confirmation, appearance, solubility, batch traceability, and red flags.
What peptide purity actually means, how HPLC measures it, how mass spectrometry confirms identity, and what the crude-through-pharmaceutical grade range represents.
Why peptide salt form (acetate vs TFA) matters, how counterions affect weight and dosing, and when acetate exchange is required for research applications.
Detailed comparison of CJC-1295 with DAC and without DAC (Mod GRF 1-29): albumin binding, half-life, GH release patterns, and the physiological significance of pulsatility.
Compare tesamorelin and sermorelin in GHRH-pathway research: molecular design, endpoint focus, and how to choose between pure axis characterization and metabolic endpoint framing.
Compare BPC-157 (angiogenesis-driven repair) and GHK-Cu (copper-mediated gene expression modulation): molecular differences, healing mechanisms, and research fit.
Compare GHK-Cu (ECM remodeling, gene expression modulation) and TB-500 (actin dynamics, cell migration): different repair-layer frameworks and research applications.
Compare KPV (anti-inflammatory tripeptide) and BPC-157 (regenerative pentadecapeptide): different mechanistic emphasis, research breadth, and protocol-design fit.
Compare MOTS-c (mitochondrial-derived peptide) and semaglutide (GLP-1 receptor agonist): fundamentally different research classes, study intent, and evidence maturity.
Answer-first guide to peptide dosage ranges, reconstitution logic, unit mistakes, and protocol interpretation.
Practical guide to peptide half-life, pharmacokinetic assumptions, and why timing claims differ across protocols.
Global-style regulatory explainer for peptides, including approval nuance, prescription context, and research-only labeling.
Evidence-first adipotide explainer focused on research status, safety uncertainty, and translational limitations.
Focused thymalin guide for dosage, reconstitution, storage assumptions, and protocol interpretation.
Educational guide to Fragment 176-191 covering the questions users actually search: dosage, half-life, side effects, and mechanism.
Hexarelin guide built around actual user intent: dosing, timing, GH-axis comparison, and protocol interpretation.
Mod GRF 1-29 article designed for dosage-chart, mechanism, and protocol comparison intent.
IGF-1 DES explainer focused on half-life, dose charts, and evidence-aware interpretation.
Matrixyl guide designed for cosmetic peptide search intent, mechanism questions, and protocol-style confusion.
Evidence-first guide to semaglutide covering mechanism, clinical outcomes, tolerability, and status context.
Head-to-head educational comparison of semaglutide and tirzepatide across mechanism, outcomes, and practical constraints.
Comparison guide separating mechanistic rationale from current evidence quality for BPC-157 and TB-500.
Safety-oriented guide to common side-effect patterns, evidence quality, and interpretation limits across peptide classes.
Regulatory explainer clarifying approved uses, research-only products, and common misunderstandings in peptide markets.
Educational math framework for concentration, unit conversion, and protocol planning consistency.
Research summary of nootropic peptides, neuroprotection hypotheses, and translational limitations.
Scientific overview of GLP-1 and dual-agonist metabolic peptides, mechanism, outcomes, and limitations.
Evidence-focused review of BPC-157 and TB-500 research with mechanism and data-quality context.
Comprehensive analysis of GHRPs and GHRHs, including mechanism-level differences and evidence gaps.
Methodology for solvent selection, concentration planning, and peptide dissolution quality control.
Technical guidelines for maintaining lyophilized peptide integrity and reducing degradation risk.
An advanced exploration of peptide synthesis, biological signaling, and modern research applications.